IL10 and cancer: A higher than median expression of the immunosuppressive cytokine IL-10 in treatment-naive serum was associated with a shortened survival time, in agreement with other studies in gastrointestinal cancers and a meta-analysis of 21 studies on 1788 patients with various cancer types, which showed that high serum IL-10 was associated with worse clinical outcomes [48].